Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus InfectionLine K. Vibholm, Ole S. Søgaard, Jørgen Agnholt et al.|Clinical Infectious Diseases|2017Cited by 146
Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapyThomas S. Uldrick, Sharon R. Lewin, Scott V. Adams et al.|Science Translational Medicine|2022Cited by 101
Memory CD4+ T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latencyThomas A. Rasmussen, Sharon R. Lewin, Jennifer M. Zerbato et al.|Cell Reports Medicine|2022Cited by 38
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controlsJames McMahon, Sharon R. Lewin, Jennifer M. Zerbato et al.|EBioMedicine|2021Cited by 21